In the I-SPY2 trial, a combination of durvalumab and olaparib added to standard paclitaxel neoadjuvant chemotherapy (durvalumab/olaparib/paclitaxel—DOP) was investigated in stage II-III HER2-negative breast cancer. Here, ERBB2 is linked to breast cancer.